Answers are grounded in this paper and cite their sources.
Denosumab is associated with a significantly higher risk of developing MRONJ compared to ZA. Nevertheless, no differences were found in its prognoses.
No takes yet. Share an insight, caveat, or question.
Limones et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: